Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
Saved in:
| Title: | Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. |
|---|---|
| Authors: | Weinstock-Guttman B; University at Buffalo, Buffalo, NY, USA., Bermel R; Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA., Cutter G; University of Alabama at Birmingham, Birmingham, AL, USA., Freedman MS; Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada., Leist TP; Thomas Jefferson University, Philadelphia, PA, USA., Ma X; Genentech, Inc., South San Francisco, CA, USA., Kile D; Genentech, Inc., South San Francisco, CA, USA., Musch B; Genentech, Inc., South San Francisco, CA, USA., Reder AT; University of Chicago, Chicago, IL, USA., Wolinsky JS; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Apr; Vol. 28 (5), pp. 790-800. Date of Electronic Publication: 2021 Aug 12. |
| Publication Type: | Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
